Blood Brain Barrier Transport Mechanisms represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.
The blood-brain barrier (BBB) is a dynamic interface that regulates the exchange of molecules between the bloodstream and the central nervous system (CNS). Understanding BBB transport mechanisms is essential for developing effective therapeutics for neurodegenerative diseases, as over 98% of small molecule drugs and nearly all large biologic therapeutics cannot cross the BBB via passive diffusion[1].
The BBB employs multiple transport mechanisms to maintain CNS homeostasis while selectively permitting essential molecules:
Paracellular transport occurs between endothelial cells through tight junctions and is typically restricted to small water-soluble molecules[2].
The tight junctional complex consists of:
| Protein | Function | Clinical Relevance |
|---|---|---|
| Claudin-5 | Forms pores allowing <800 Da molecules | Target for transient opening in stroke[3] |
| Occludin | Structural integrity, signaling | Downregulated in AD[4] |
| ZO-1 | Scaffolding protein | Link to actin cytoskeleton |
| ZO-2/3 | Additional scaffolding | Tissue-specific regulation |
The paracellular route is largely impermeable to molecules >800 Da, making it unsuitable for therapeutic delivery of biologics.
Lipophilic molecules can diffuse directly through the endothelial cell membrane based on lipophilicity, molecular size, and polar surface area[5].
For optimal BBB penetration via passive diffusion:
While small molecules like caffeine and nicotine readily cross via passive diffusion, most CNS drug candidates fail these criteria. Additionally, the expression of efflux transporters (see below) can override passive permeability.
Endogenous nutrient transporters facilitate passage of essential molecules required for CNS function[6].
| Transporter | Substrate | Therapeutic Exploitation |
|---|---|---|
| GLUT1 (SLC2A1) | Glucose | Glucose analogs for imaging |
| LAT1 (SLC7A5) | Large neutral amino acids | Prodrugs (e.g., levodopa)[7] |
| MCT1 (SLC16A1) | Monocarboxylic acids | Lactate, ketone bodies |
| OAT1/3 (SLC22A) | Organic anions | Drug clearance |
| CNT2 (SLC28A2) | Nucleosides | Antiviral therapy |
The LAT1 transporter is particularly valuable for drug delivery as it accepts a broad range of amino acid-like structures, enabling the development of amino acid prodrug strategies.
RMT is the primary mechanism for biological therapeutics to cross the BBB. This process involves: (1) binding of ligand/receptor to apical membrane, (2) internalization into clathrin-coated pits, (3) transcytosis across endothelial cell, and (4) release at the basolateral membrane[8].
The most extensively studied RMT target:
| Drug | Target | Mechanism | Status |
|---|---|---|---|
| Lecanemab | Aβ plaques | Anti-amyloid (RMT contribution) | FDA approved |
| Aducanumab | Aβ plaques | Anti-amyloid | FDA approved |
| Tominersen | HTT | ASO (some CNS penetration) | Halted |
| Zolgensma | SMN1 | AAV9 gene therapy | FDA approved |
This mechanism involves electrostatic interactions between cationic molecules and the negatively charged endothelial cell membrane[12].
ATP-binding cassette (ABC) transporters actively pump substrates back into the bloodstream, representing a major obstacle to CNS drug delivery[13].
| Transporter | Gene | Substrates |
|---|---|---|
| P-glycoprotein (P-gp) | ABCB1 | Indomethacin, colchicine, many chemotherapeutics |
| Breast Cancer Resistance Protein (BCRP) | ABCG2 | Methotrexate, topotecan |
| Multidrug Resistance-Associated Proteins (MRPs) | ABCC1-9 | Glucuronide/glutathione conjugates |
The BBB exists within a complex neurovascular unit comprising multiple cell types that collectively regulate CNS homeostasis[15].
| Cell Type | Function | BBB Regulation |
|---|---|---|
| Endothelial cells | Form the physical barrier, express transporters | Tight junctions, enzymes |
| Pericytes | Regulate capillary diameter, BBB development | Cover 80-90% of capillary surface |
| Astrocytes | Induce and maintain BBB properties | Release factors (GFAP, AQP4) |
| Neurons | Control local blood flow | Activity-dependent regulation |
| Microglia | Immune surveillance | May compromise BBB in disease |
| Strategy | Transport Route | Examples |
|---|---|---|
| Prodrug design | Carrier-mediated (LAT1) | Levodopa, valacyclovir |
| Nanoparticle delivery | RMT (apoE coating) | Lipid nanoparticles, polymeric NPs |
| Brain shuttle antibodies | RMT (TfR, LRP1) | Roche, Denali platforms |
| Transient opening | Paracellular | Cereport, focus on safety |
| Inhibition | Efflux pumps | P-gp modulators (experimental) |
| Drug | Molecular Weight (Da) | LogP | BBB Permeability | Primary Mechanism |
|---|---|---|---|---|
| Donepezil | 379 | 4.5 | High | Passive diffusion |
| Memantine | 179 | 3.3 | High | Passive diffusion |
| Levodopa | 197 | 2.4 | Moderate | LAT1 carrier |
| Baclofen | 214 | -0.9 | Low | Limited (P-gp substrate) |
| Ranibizumab | 48,000 | N/A | Very Low | Minimal (requires RMT) |
| Antibody therapeutics | ~150,000 | N/A | Very Low | Requires RMT engineering |
BBB breakdown is a hallmark of multiple neurodegenerative diseases[16]:
See also: BBB Dysfunction Pathway, Pericytes, Astrocytes, Tight Junctions
Emerging strategies to enhance BBB transport include:
The study of Blood Brain Barrier Transport Mechanisms has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx. 2005;2(1):3-14. PMID:15717053.
Nitta T, Hata M, Gotoh S, et al. Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. J Cell Biol. 2003;161(3):653-660. PMID:12743111.
Ronaldson PT, Davis TP. Targeting transporters: promoting blood-brain barrier repair in response to oxidative stress. Brain Res Bull. 2020;153:190-202. PMID:31454549.
Zipser BD, Johanson CE, Gonzalez L, et al. Microvascular injury and blood-brain barrier leakage in Alzheimer's disease. Neurobiol Aging. 2007;28(7):977-986. PMID:16787641.
Fischer H, Gottschlich R, Seelig A. Blood-brain barrier permeation: molecular parameters governing passive diffusion. J Membr Biol. 1998;165(3):201-217. PMID:9776902.
O'Brien FE, Dinan TG, Griffin BT, Cryan JF. Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and genetic findings. Brain Res Bull. 2018;141:97-106. PMID:28888930.
Gynther M, Laine K, Ropponen J, et al. Large neutral amino acid transporter enables brain drug delivery via prodrugs. J Med Chem. 2008;51(4):932-936. PMID:18215013.
Lajoie JM, Shusta EV. Targeting receptor-mediated transport for delivery of biologics across the blood-brain barrier. Annu Rev Pharmacol Toxicol. 2015;55:613-631. PMID:25292430.
Niewoehner J, Bohrmann B, Collin L, et al. Increased brain penetration and potency of a therapeutic antibody using a monovalent bispecific antibody fragment. Neuron. 2014;81(1):49-60. PMID:24411733.
Regina A, Demeule M, Che C, et al. Antitumour activity of ANG1005, a conjugate between paclitaxel and the angiopep-2 peptide. Eur J Cancer. 2008;44(15):2194-2203. PMID:18752948.
Boado RJ, Zhang Y, Zhang Y, et al. Fusion protein for delivery of清净 neurotrophic factors across the human blood-brain barrier. Biotechnol Bioeng. 2007;98(6):1199-1207. PMID:17497831.
Vorbrodt AW. Role of micropinocytosis in the function of the blood-brain barrier. Folia Histochem Cytobiol. 2012;50(3):354-359. PMID:23042268.
Löscher W, Potschka H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol. 2005;76(1):22-76. PMID:15800791.
Fellner S, Bauer B, Miller DS, et al. Drug transport across the blood-brain barrier using P-glycoprotein: impact of the ABCB1 genotype. Clin Pharmacol Ther. 2002;71(5):359-365. PMID:12011824.
Abbott NJ, Rönnbäck L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci. 2006;7(1):41-53. PMID:16371949.
Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron. 2008;57(2):178-201. PMID:18215617.
Sagare AP, Bell RD, Zhao Z, et al. Pericyte dysfunction contributes to chronic neurovascular dysfunction in Alzheimer's disease. Brain. 2013;136(Pt 9):2707-2722. PMID:23884810.
🟡 Moderate Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 17 references |
| Replication | 0% |
| Effect Sizes | 50% |
| Contradicting Evidence | 0% |
| Mechanistic Completeness | 50% |
Overall Confidence: 44%